Mr. Trevor Burns reports

CARDIOL THERAPEUTICS TO WEBCAST VIRTUAL ANNUAL GENERAL MEETING ON JUNE 28TH AT 4:30 P.M. EDT

Cardiol Therapeutics Inc.'s virtual annual general meeting of shareholders (AGM) will be webcast on June 28, 2023, at 4:30 p.m. EDT.

Cardiol Therapeutics 2023 AGM

When:  June 28, 2023, at 4:30 p.m. EDT

Where:  virtual meeting only via live audio webcast on-line

Additional information on the AGM, including details on how to participate and vote, is available on the company's website.

About Cardiol Therapeutics Inc.

Cardiol is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The company's lead drug candidate, the CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis and heart failure.

Cardiol has received investigational new drug application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: (i) a phase II multicentre open-label pilot study in recurrent pericarditis (inflammation of the pericardium), which is associated with symptoms including debilitating chest pain, shortness of breath and fatigue, and results in physical limitations, reduced quality of life, emergency department visits and hospitalizations; and (ii) a phase II multinational, randomized, double-blind, placebo-controlled trial (the Archer trial) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age.

Cardiol is also developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure -- a leading cause of death and hospitalization in the developed world, with associated health care costs in the United States exceeding $30-billion annually.

We seek Safe Harbor.